{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:27:11Z","timestamp":1791919631125,"version":"4.3.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T00:00:00Z","timestamp":1655769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CAR T-cell therapy is well tolerated and effective in patients with Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL). However, even second- generation anti-CD30 CAR T-cells with CD28 (28z) costimulatory domains failed to achieve the desired rate of complete responses. In the present study, we developed second-generation (CD28z) and third-generation (CD28BBz) CAR T-cells targeting CD30 and investigated their efficacy in vitro and in vivo. Both of CD28z and CD28BBz anti-CD30 CAR T cells were similar regarding amplification, T cell subsets distribution, T cell activity, effector\/memory and exhaustion. However, we found that the 28BBz anti-CD30 CAR T-cells persist long-term, specifically homing to the tumor and mediating powerful antitumor activity in tumor xenograft models. Subsequently, we also demonstrated that the third generation anti-CD30 CAR T-cells have miner side effects or potential risks of tumorigenesis. Thus, anti-CD30 CAR T-cells represent a safe and effective treatment for Hodgkin lymphoma. <\/jats:p>","DOI":"10.1038\/s41598-022-14523-0","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T19:39:56Z","timestamp":1655840396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity"],"prefix":"10.1038","volume":"12","author":[{"given":"Shangkun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaojiang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lifang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangzhou","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjiao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingqi","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiqin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiapeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongcun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,21]]},"reference":[{"key":"14523_CR1","doi-asserted-by":"crossref","unstructured":"Hodgkin lymphoma. Nat. Rev. Dis. Primers 6(1), 62 (2020).","DOI":"10.1038\/s41572-020-0203-z"},{"issue":"2","key":"14523_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3322\/caac.21438","volume":"68","author":"S Shanbhag","year":"2018","unstructured":"Shanbhag, S. & Ambinder, R. F. Hodgkin lymphoma: A review and update on recent progress. CA Cancer J. Clin. 68(2), 116\u2013132 (2018).","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"14523_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/nrclinonc.2012.91","volume":"9","author":"P Borchmann","year":"2012","unstructured":"Borchmann, P., Eichenauer, D. A. & Engert, A. State of the art in the treatment of Hodgkin lymphoma. Nat. Rev. Clin. Oncol. 9(8), 450 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7","key":"14523_CR4","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert, A. et al. Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma. N. Engl. J. Med. 363(7), 640\u2013652 (2010).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"14523_CR5","first-page":"497","volume":"2009","author":"J Kuruvilla","year":"2009","unstructured":"Kuruvilla, J. Standard therapy of advanced Hodgkin lymphoma. ASH Educ. Program Book 2009(1), 497\u2013506 (2009).","journal-title":"ASH Educ. Program Book"},{"issue":"8","key":"14523_CR6","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3390\/cancers11081071","volume":"11","author":"TP Vassilakopoulos","year":"2019","unstructured":"Vassilakopoulos, T. P. et al. Immunotherapy in Hodgkin lymphoma: Present status and future strategies. Cancers 11(8), 1071 (2019).","journal-title":"Cancers"},{"issue":"7","key":"14523_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/nbt.2289","volume":"30","author":"PD Senter","year":"2012","unstructured":"Senter, P. D. & Sievers, E. L. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat. Biotechnol. 30(7), 631\u2013637 (2012).","journal-title":"Nat. Biotechnol."},{"issue":"19","key":"14523_CR8","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes, A. et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N. Engl. J. Med. 363(19), 1812\u20131821 (2010).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"14523_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1756-8722-7-24","volume":"7","author":"NL Bartlett","year":"2014","unstructured":"Bartlett, N. L. et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J. Hematol. Oncol. 7(1), 24 (2014).","journal-title":"J. Hematol. Oncol."},{"issue":"18","key":"14523_CR10","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes, A. et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J. Clin. Oncol. 30(18), 2183 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"14523_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nri1842","volume":"6","author":"L Gattinoni","year":"2006","unstructured":"Gattinoni, L., Powell, D. J., Rosenberg, S. A. & Restifo, N. P. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6(5), 383\u2013393 (2006).","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"14523_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nri3191","volume":"12","author":"NP Restifo","year":"2012","unstructured":"Restifo, N. P., Dudley, M. E. & Rosenberg, S. A. Adoptive immunotherapy for cancer: Harnessing the T cell response. Nat. Rev. Immunol. 12(4), 269\u2013281 (2012).","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"14523_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.blre.2015.10.003","volume":"30","author":"S Gill","year":"2016","unstructured":"Gill, S., Maus, M. V. & Porter, D. L. Chimeric antigen receptor T cell therapy: 25years in the making. Blood Rev. 30(3), 157\u2013167 (2016).","journal-title":"Blood Rev."},{"issue":"303","key":"14523_CR14","doi-asserted-by":"publisher","first-page":"303ra139-303ra1","DOI":"10.1126\/scitranslmed.aac5415","volume":"7","author":"DL Porter","year":"2015","unstructured":"Porter, D. L. et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7(303), 303ra139-303ra139 (2015).","journal-title":"Sci. Transl. Med."},{"issue":"16","key":"14523_CR15","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp, S. A. et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368(16), 1509\u20131518 (2013).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"14523_CR16","doi-asserted-by":"publisher","first-page":"473, 475, 477,","DOI":"10.1097\/00002371-199911000-00001","volume":"22","author":"A Hombach","year":"1999","unstructured":"Hombach, A. et al. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin\u2019s lymphoma-associated CD30 antigen. J. Immunother. 22(6), 473, 475, 477, 479 (1999).","journal-title":"J. Immunother."},{"issue":"5","key":"14523_CR17","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","volume":"23","author":"C-M Wang","year":"2017","unstructured":"Wang, C.-M. et al. Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: An open-label phase I trial. Clin. Cancer Res. 23(5), 1156\u20131166 (2017).","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"14523_CR18","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos, C. A. et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor\u2013redirected lymphocytes. J. Clin. Investig. 127(9), 3462\u20133471 (2017).","journal-title":"J. Clin. Investig."},{"key":"14523_CR19","first-page":"JCO2001342-JCO2","volume":"2020","author":"CA Ramos","year":"2020","unstructured":"Ramos, C. A. et al. Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma. J. Clin. Oncol. 2020, JCO2001342\u2013JCO2001342 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"14523_CR20","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","volume":"26","author":"CA Ramos","year":"2018","unstructured":"Ramos, C. A. et al. In vivo fate and activity of second-versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin\u2019s lymphomas. Mol. Ther. 26(12), 2727\u20132737 (2018).","journal-title":"Mol. Ther."},{"issue":"12","key":"14523_CR21","doi-asserted-by":"publisher","first-page":"13904","DOI":"10.1136\/bmjopen-2016-013904","volume":"6","author":"X-Y Tang","year":"2016","unstructured":"Tang, X.-Y. et al. Third-generation CD28\/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: A non-randomised, open-label phase I trial protocol. BMJ Open 6(12), 13904 (2016).","journal-title":"BMJ Open"},{"issue":"24","key":"14523_CR22","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1158\/1078-0432.CCR-18-0426","volume":"24","author":"G Enblad","year":"2018","unstructured":"Enblad, G. et al. A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia. Clin. Cancer Res. 24(24), 6185\u20136194 (2018).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"14523_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41408-020-0274-9","volume":"10","author":"D Wang","year":"2020","unstructured":"Wang, D. et al. Anti-CD30 chimeric antigen receptor T cell therapy for relapsed\/refractory CD30+ lymphoma patients. Blood Cancer J. 10(1), 8 (2020).","journal-title":"Blood Cancer J."},{"key":"14523_CR24","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11523-020-00729-7","volume":"15","author":"S Ding","year":"2020","unstructured":"Ding, S. et al. Targeting CD79b for chimeric antigen receptor T-cell therapy of B-cell lymphomas. Target. Oncol. 15, 365 (2020).","journal-title":"Target. Oncol."},{"key":"14523_CR25","doi-asserted-by":"publisher","first-page":"e38314","DOI":"10.7554\/eLife.38314","volume":"7","author":"H Zhu","year":"2018","unstructured":"Zhu, H. et al. T-ALL leukemia stem cell\u2019stemness\u2019 is epigenetically controlled by the master regulator SPI1. Elife 7, e38314 (2018).","journal-title":"Elife"},{"issue":"22","key":"14523_CR26","doi-asserted-by":"publisher","first-page":"E4990","DOI":"10.1073\/pnas.1716788115","volume":"115","author":"DF Tucker","year":"2018","unstructured":"Tucker, D. F. et al. Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles. Proc. Natl. Acad. Sci. 115(22), E4990\u2013E4999 (2018).","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"8","key":"14523_CR27","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/nprot.2010.87","volume":"5","author":"A Paruzynski","year":"2010","unstructured":"Paruzynski, A. et al. Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat. Protoc. 5(8), 1379 (2010).","journal-title":"Nat. Protoc."},{"key":"14523_CR28","doi-asserted-by":"crossref","unstructured":"Horie, R., & Watanabe, T. CD30: Expression and function in health and disease. in Seminars in Immunology. 457\u2013470. (Elsevier, 2021).","DOI":"10.1006\/smim.1998.0156"},{"issue":"9844","key":"14523_CR29","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/S0140-6736(12)60605-9","volume":"380","author":"KR Shankland","year":"2012","unstructured":"Shankland, K. R., Armitage, J. O. & Hancock, B. W. Non-hodgkin lymphoma. Lancet 380(9844), 848\u2013857 (2012).","journal-title":"Lancet"},{"issue":"6","key":"14523_CR30","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T. et al. CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24(6), 731\u2013738 (2018).","journal-title":"Nat. Med."},{"issue":"13","key":"14523_CR31","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","volume":"4","author":"K Wudhikarn","year":"2020","unstructured":"Wudhikarn, K. et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 4(13), 3024\u20133033 (2020).","journal-title":"Blood Adv."},{"issue":"7709","key":"14523_CR32","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558(7709), 307\u2013312 (2018).","journal-title":"Nature"},{"issue":"10","key":"14523_CR33","doi-asserted-by":"publisher","first-page":"5442","DOI":"10.1073\/pnas.1919259117","volume":"117","author":"W Wang","year":"2020","unstructured":"Wang, W. et al. Joint profiling of chromatin accessibility and CAR-T integration site analysis at population and single-cell levels. Proc. Natl. Acad. Sci. 117(10), 5442\u20135452 (2020).","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7696","key":"14523_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/nature25795","volume":"555","author":"X Ma","year":"2018","unstructured":"Ma, X. et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature 555(7696), 371\u2013376 (2018).","journal-title":"Nature"},{"issue":"8","key":"14523_CR35","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49(8), 1211 (2017).","journal-title":"Nat. Genet."},{"issue":"9","key":"14523_CR36","doi-asserted-by":"publisher","first-page":"e603","DOI":"10.1038\/bcj.2017.85","volume":"7","author":"C Van der Weyden","year":"2017","unstructured":"Van der Weyden, C., Pileri, S., Feldman, A., Whisstock, J. & Prince, H. Understanding CD30 biology and therapeutic targeting: A historical perspective providing insight into future directions. Blood Cancer J. 7(9), e603\u2013e603 (2017).","journal-title":"Blood Cancer J."},{"issue":"18","key":"14523_CR37","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/blood-2014-03-561878","volume":"123","author":"MD Gandhi","year":"2014","unstructured":"Gandhi, M. D. et al. Pancreatitis in patients treated with brentuximab vedotin: A previously unrecognized serious adverse event. Blood 123(18), 2895\u20132897 (2014).","journal-title":"Blood"},{"issue":"1","key":"14523_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40268-014-0036-x","volume":"14","author":"SAM Urru","year":"2014","unstructured":"Urru, S. A. M. et al. Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: A case report. Drugs R&D 14(1), 9\u201311 (2014).","journal-title":"Drugs R&D"},{"key":"14523_CR39","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/mto.2016.14","volume":"3","author":"D Abate-Daga","year":"2016","unstructured":"Abate-Daga, D. & Davila, M. L. CAR models: Next-generation CAR modifications for enhanced T-cell function. Mol. Ther.-Oncol. 3, 16014 (2016).","journal-title":"Mol. Ther.-Oncol."},{"issue":"2","key":"14523_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12910","volume":"92","author":"D Feng","year":"2020","unstructured":"Feng, D. & Sun, J. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed\/refractory multiple myeloma. Scand. J. Immunol. 92(2), e12910 (2020).","journal-title":"Scand. J. Immunol."},{"issue":"11","key":"14523_CR41","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1038\/mt.2013.154","volume":"21","author":"DS Ritchie","year":"2013","unstructured":"Ritchie, D. S. et al. Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia. Mol. Ther. 21(11), 2122\u20132129 (2013).","journal-title":"Mol. Ther."},{"issue":"1","key":"14523_CR42","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2326-6066.CIR-14-0192","volume":"3","author":"SP Santoro","year":"2015","unstructured":"Santoro, S. P. et al. T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression. Cancer Immunol. Res. 3(1), 68\u201384 (2015).","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"14523_CR43","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1158\/2326-6066.CIR-15-0230","volume":"4","author":"AH Long","year":"2016","unstructured":"Long, A. H. et al. Reduction of MDSCs with all-trans retinoic acid improves CAR therapy efficacy for sarcomas. Cancer Immunol. Res. 4(10), 869\u2013880 (2016).","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"14523_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","volume":"6","author":"A Morello","year":"2016","unstructured":"Morello, A., Sadelain, M. & Adusumilli, P. S. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 6(2), 133\u2013146 (2016).","journal-title":"Cancer Discov."},{"issue":"1","key":"14523_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.96976","volume":"3","author":"S Guedan","year":"2018","unstructured":"Guedan, S. et al. Enhancing CAR T cell persistence through ICOS and 4\u20131BB costimulation. JCI insight. 3(1), 1 (2018).","journal-title":"JCI insight."},{"issue":"3","key":"14523_CR46","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/ijms20030660","volume":"20","author":"R Klapdor","year":"2019","unstructured":"Klapdor, R. et al. Characterization of a novel third-generation anti-CD24-CAR against ovarian cancer. Int. J. Mol. Sci. 20(3), 660 (2019).","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"14523_CR47","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","volume":"26","author":"CA Ramos","year":"2018","unstructured":"Ramos, C. A. et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin\u2019s lymphomas. Mol. Ther. 26(12), 2727\u20132737 (2018).","journal-title":"Mol. Ther."},{"issue":"12","key":"14523_CR48","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1089\/hum.2013.209","volume":"25","author":"D Abate-Daga","year":"2014","unstructured":"Abate-Daga, D. et al. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum. Gene Ther. 25(12), 1003\u20131012 (2014).","journal-title":"Hum. Gene Ther."},{"issue":"544","key":"14523_CR49","doi-asserted-by":"publisher","first-page":"6753","DOI":"10.1126\/scisignal.aat6753","volume":"11","author":"AI Salter","year":"2018","unstructured":"Salter, A. I. et al. Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function. Sci. Signal. 11(544), 6753 (2018).","journal-title":"Sci. Signal."},{"key":"14523_CR50","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1172\/jci.insight.121322","volume":"3","author":"G Li","year":"2018","unstructured":"Li, G. et al. 4-1BB enhancement of CAR T function requires NF-\u03baB and TRAFs. JCI Insight 3, 18 (2018).","journal-title":"JCI Insight"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14523-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14523-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14523-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T06:14:01Z","timestamp":1669356841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-14523-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,21]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["14523"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-14523-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,21]]},"assertion":[{"value":"15 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10488"}}